VCYT Quote, Financials, Valuation and Earnings

Insight Molecular Diagnostics, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -4174.62%. Veracyte, Inc.'s return on equity of 2.52% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 12.77%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 7.36%. Given that Veracyte, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe Veracyte, Inc. is more attractive than Insight Molecular Diagnostics, Inc..

Veracyte, Inc. has a beta of 1.876, which suggesting that the stock is 87.569% more volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.885%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. Veracyte, Inc.'s net income of $19.1M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 111.35x while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 6.79x versus 39.67x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -774.52%. Veracyte, Inc.'s return on equity of 2.52% beat ProPhase Labs, Inc.'s return on equity of -90.24%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 12.77%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 37958.47%. Given that ProPhase Labs, Inc. has higher upside potential than Veracyte, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.876, which suggesting that the stock is 87.569% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Veracyte, Inc.'s net income of $19.1M is higher than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Veracyte, Inc.'s price-to-earnings ratio is 111.35x while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 6.79x versus 0.25x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of 14.58%. Veracyte, Inc.'s return on equity of 2.52% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 12.77%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $652.61 which suggests that it could grow by 4.25%. Given that Veracyte, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Veracyte, Inc. is more attractive than Thermo Fisher Scientific, Inc..

Veracyte, Inc. has a beta of 1.876, which suggesting that the stock is 87.569% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.907, suggesting its less volatile than the S&P 500 by 9.346%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.28% to investors and pays a quarterly dividend of $0.43 per share. Veracyte, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veracyte, Inc. quarterly revenues are $131.9M, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Veracyte, Inc.'s net income of $19.1M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Veracyte, Inc.'s price-to-earnings ratio is 111.35x while Thermo Fisher Scientific, Inc.'s PE ratio is 36.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 6.79x versus 5.43x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of 14.51% compared to Veracyte, Inc.'s net margin of -2.87%. Veracyte, Inc.'s return on equity of 2.52% beat XWELL, Inc.'s return on equity of -224.93%.

Veracyte, Inc. has a consensus price target of $47.67, signalling upside risk potential of 12.77%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1927.81%. Given that XWELL, Inc. has higher upside potential than Veracyte, Inc., analysts believe XWELL, Inc. is more attractive than Veracyte, Inc..

Veracyte, Inc. has a beta of 1.876, which suggesting that the stock is 87.569% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.

Veracyte, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veracyte, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Veracyte, Inc. quarterly revenues are $131.9M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Veracyte, Inc.'s net income of $19.1M is higher than XWELL, Inc.'s net income of -$211K. Notably, Veracyte, Inc.'s price-to-earnings ratio is 111.35x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veracyte, Inc. is 6.79x versus 0.06x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.